<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512185</url>
  </required_header>
  <id_info>
    <org_study_id>15-9075</org_study_id>
    <nct_id>NCT02512185</nct_id>
  </id_info>
  <brief_title>Towards Optimal Prescription of Chemotherapy in Prostate Cancer</brief_title>
  <acronym>TOPCOP</acronym>
  <official_title>TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the impact of modern treatments for metastatic Castrate Resistant&#xD;
      Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function,&#xD;
      objective physical function, and falls. Additionally, the investigators study whether frailty&#xD;
      is associated with worse outcomes, and whether it is possible to predict the risk of severe&#xD;
      chemotherapy toxicity in older men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary aims are (a) to examine the impact of pre-treatment frailty on 'elder-relevant'&#xD;
      outcomes including daily function, objective physical function, falls, quality of life (QOL),&#xD;
      and early treatment discontinuation; (b) to determine whether the Hurria/Cancer and Aging&#xD;
      Research Group (CARG) tool is able to predict severe (grade 3+) chemotherapy toxicity in men&#xD;
      starting chemotherapy. Our secondary aim is to understand the impact of abiraterone and&#xD;
      enzalutamide on 'elder-relevant' outcomes.&#xD;
&#xD;
      This is a prospective multicentre observational study. The investigators will enroll men age&#xD;
      65 or older with mCRPC who are starting (a) first-line chemotherapy; (b) abiraterone; or (c)&#xD;
      enzalutamide. Assessments will occur prior to starting treatment and every 2 months&#xD;
      thereafter until the end of treatment.&#xD;
&#xD;
      As treatment options become more complex in older men with mCRPC, understanding and&#xD;
      predicting a wide range of treatment toxicities is important and will aid decision-making and&#xD;
      management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Daily function assessed by questionnaires</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Daily function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective physical function</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Will be assessed by 3 physical performance measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3+ toxicity using Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of falls provided by the participant</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Falls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body fat percentage will be measured using a Tanita 300A analyzer</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Body composition analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>FACT-G and FACT-P (specific for prostate cancer) questionnaires will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment (MoCA test) and Trail making tests A&amp;B</measure>
    <time_frame>Participants will be followed for the duration of treatment up to 2 years</time_frame>
    <description>Cognition composite</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">206</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <description>Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone</arm_group_label>
    <description>Men with mCRPC starting Abiraterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <description>Men with mCRPC starting Enzalutamide</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Men 65 and older starting first line chemotherapy, or Abiraterone, or Enzalutamide for&#xD;
        mCRPC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 65 years of age&#xD;
&#xD;
          2. Diagnosed with prostate cancer with evidence of clinical and/or radiographic evidence&#xD;
             of progression despite adequate androgen deprivation therapy and achievement of&#xD;
             castration (total testosterone level &lt;1.7 nmol/L measured within 6 months of&#xD;
             enrollment)&#xD;
&#xD;
          3. Among men starting either abiraterone or enzalutamide, no prior&#xD;
             chemotherapy/abiraterone/enzalutamide. Among men starting first-line chemotherapy,&#xD;
             commencing docetaxel but can have had either prior abiraterone or enzalutamide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to speak English fluently.&#xD;
&#xD;
          2. Severe neuropsychiatric abnormalities that prevent study participation.&#xD;
&#xD;
          3. Limited life expectancy (&lt;3 months) as estimated by the primary oncologist.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre -KGH</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>mCRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

